It is true that once a nerve cell is dead, nothing can be done for that cell.  However the hope is that the technology that Mirella and Alice are using will ultimately enable cells to be produced that can be put into the nervous system, heart and other organs to replace the dead cells.
I have cc'd Mirella and Alice to ensure they agree with what I have said and if they are then I am very happy for this to be emailed to the broader FA community.
 
Regards,
 
Martin
 
Professor Martin Delatycki
Director, Clinical Genetics, Austin Health
Heidelberg Repatriation Hospital
PO Box 5444, Heidelberg West, 3081
Victoria, Australia
Director, Bruce Lefroy Centre for Genetic Health Research
Murdoch Childrens Research Institute
Flemington Road Parkville, 3052
Victoria Australia


________________________________________

From: Jennifer Callaghan
Sent: Mon 2/15/2010 3:30 PM
To: Martin Delatycki
Subject: clarification

Hi Martin
I read the latest FA breakthrough article at Monash with great excitement and hope.
It says”.... Dr Dottori and her colleague Dr Alice Pebay have ''pushed'' these cells to turn into nerve and heart cells, which can be studied to better understand the disease....”
Does this mean that nerve cells can or can’t be grown in a person with FA?
I have been told that once a nerve cell is dead,  it cannot be brought back to full function. This article gives the impression a  new nerve cell can be made from fibroblasts. 
Can you clarify this and may I publish your response?
Yours sincerely

Jenni Callaghan

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!

https://www.amazon.com/Legacy-Marie-Schlau-collective-Friedreichs-ebook/dp/B01N28AFWZ

 

Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

https://www.irbbarcelona.org/en/news/international-patient-advocates-partner-to-fund-spanish-gene-therapy-project-to-treat

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:

https://www.irbbarcelona.org/en/news/new-research-front-to-tackle-friedreichs-ataxia
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.

 

 

Go to top